Labiotech.eu

Find out what investors now look for in an AI biotech company, now that the hype has settled and AI enters a more pragmatic era. labiotech.eu/in-depth/ai-bi…

Discover the potential long-term risks caused by biotech layoffs and how biotech risk management is vital in this situation. labiotech.eu/expert-advice/…

Learn how cryopreservation improves scalability and helps CGT programs move from early development to commercial manufacturing. labiotech.eu/partner/cryopr…

Delve into the Australian biotech giant CSL's strategy to refocus a company built on complex modalities. labiotech.eu/top-pharma-str…

Discover the field of trispecific antibodies, which are currently generating strong interest across the biopharma industry. labiotech.eu/in-depth/trisp…

Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. labiotech.eu/podcast/making…

The biggest biotech acquisition deal so far in 2026 was announced in April. Deals were sealed over ADCs, small molecules, AI platforms, and T-cell engagers.   labiotech.eu/trends-news/to…

Look into what biotech companies are developing for sickle cell disease after Casgevy's approval in 2023. labiotech.eu/best-biotech/s…

Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? …ess-1620605-6393265.cloudwaysapps.com/trends-news/bl…

This is a test excerpt …ess-1620605-6393265.cloudwaysapps.com/best-biotech/t…

Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? labiotech.eu/best-biotech/b…

Let’s pick up the bagpipes as we take a look at 5 biotech companies in Scotland driving the country's flourishing life sciences scene. labiotech.eu/best-biotech/t…

This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epic Bio. labiotech.eu/podcast/how-ep…

Discover the emerging class of degrader–antibody conjugates – a modality that is drawing increasing interest from biotech companies. labiotech.eu/in-depth/degra…

We take a closer look at Gilead's pipeline strategy and dealmaking activity in 2026 as the company attempts to broaden its focus beyond HIV. labiotech.eu/top-pharma-str…

Single-cell omics is reshaping drug discovery, but turning complex data into biological insight remains slow. AI may help close the annotation gap. labiotech.eu/partner/ai-in-…

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising preclinical results. labiotech.eu/trends-news/cr…

Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. In this episode, Patrick walks us through the company’s DIAGONAL platform, and its lead program DIAG723 labiotech.eu/podcast/diagon…

AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed. labiotech.eu/trends-news/aa…

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers. labiotech.eu/in-depth/parp-…